Ms. Jennifer Che, our President and Managing Director, spoke at the Hong Kong Intellectual Property Department’s IP Training Programme on patent commercialization and technology transfer. Since 2020, the IPD has partnered with the Vocational Training Council’s Institute of Professional Education and Knowledge to arrange various IP training programmes. Other speakers include Mr. Michael Lin – a strategic business consultant & President of IIPCC, Dr. David Ai from the London School of Economics and Political Science, and Dr. Vincent Zhong, an expert in IP licensing and technology transfer who worked at Netac Technology Co., Ltd.

Jennifer’s talk, titled ‘Building a Strategic Patent Portfolio for Commercialization,’ taught professionals how to strategically build patent portfolios with a business mindset. Aside from building IP, Jennifer also focused on topics such as IP licensing, ownership transfers, enforcement, and cross-border issues.

Attendees, including IP owners and executives from startups, SMEs, and large enterprises in the innovation sector, found her talk incredibly insightful and beneficial.

We are very thankful to the IPD and PEAK/VTC for this opportunity to help build a deeper understanding of IP and commercialization in Hong Kong.

Our Past Events

Recommended Insights

Amendments to the China Patent Examination Guidelines in 2022 - Part 1: New rules for designs in view of China signing onto the Hague Agreement

2 December 2022
This year, China stepped further onto the international scene by signing on as a member of the Hague Agreement. The Hague Agreement is an international registration system allowing applicants to file a single international design application in a single language to obtain protection in over 100 designated member countries. The US has been a member […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law

22 October 2021
Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

14 July 2021
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Top crossarrow-right